Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Fortis partners with diagnostics and life sciences companies to design, validate, and manufacture solutions to solve their complex development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America. A single partner with the • Expertise to solve your most complex development problems. • Flexibility to design and validate solutions. • Scale to meet your manufacturing requirements.
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com.
Biosortia works on new drugs from deep access to the chemistry of the microbiome for immuno-oncology and immunological therapeutics.
Hyalose LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid .
Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
About Worldwide Clinical Trials Worldwide Clinical Trials is a global, midsize contract research organization (CRO) that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries. Founded in 1986 by physicians committed to advancing medical science, our full-service clinical experience ranges from early phase and bioanalytical sciences through late phase studies, post approval, and real-world evidence. Major therapeutic areas of focus include cardiovascular, metabolic, neuroscience, oncology, and rare diseases. Operating in 60+ countries with offices in North and South America, Eastern and Western Europe, and Asia, Worldwide is powered by its more than 3,000 employee experts. For more information, please visit www.worldwide.com or connect with us on Twitter, LinkedIn, Facebook, and Instagram.
Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com.
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.
Philadelphia-based biotechnology company .
Tissuetech offers regenerative amniotic tissue-based products for ophthalmology, optometry, musculoskeletal, and wound care markets.
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics.
Pebble Labs Inc. is creating safe and effective biological solutions to sustainably protect yields and quality in food production. We harness naturally occurring microbes from the microbiomes of crops of interest to deliver the power of RNA for solutions that target formidable pests and diseases.
DCN Dx specializes in contract development of rapid point of care tests. We offer a variety of services and products that assist our clients in the design and development of user-centric, high performing diagnostic devices. Contract development of rapid immunoassays is at the core of all that we do at DCN Dx. We focus on lateral flow, flow through, and microfuidic formats. Our staff has unparalleled experience in developing assays with tough specifications, regarding high sensitivity, quantification, multiplexing and reader integration. Our ISO 9001:2015 compliant development process allows for close integration of assay and device development pathways, which ensures the best chance of commercial success for the product. As well as developing the assay itself, DCN Dx's integrated engineering team will design, develop and integrate your entire device. The engineers work closely with our scientists to create cassettes and sample handling devices that enhance the performance of your assay and meet all end-user specifications. We deliver the product, not just the parts. DCN Dx also offers a variety of products and services to assist our clients at any stage of development, including: - Custom, private education and training courses in lateral flow technology, during which we teach the details of how to develop and manufacture rapid assays. - Consulting services to assist with any aspect of rapid assay development, manufacturing, regulation and commercialization. - Custom protein-protein, protein-particle, small molecule-protein and small molecule- particle conjugations. - Lateral flow material starter kits, conjugation kits, reagents, cassettes and materials for use during rapid assay development. DCN Dx represents a single source that can help you manage and deliver completely validated assay platforms. CONTACT US: www.dcndx.com [email protected] (760) 804-3886
Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In 2022, Hound Labs will launch its first ultra-sensitive point-of-care solution – the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis use rapidly and accurately by testing breath on-site. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.
Ambrx Inc., is a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code. Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next-generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease.
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit
Pioneering Diagnostics A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market.
BioSentinel develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT).
